PHARMACY PRE-AUTHORIZATION CRITERIA

DRUG (S)	**Zortress (everolimus)**
POLICY #	**22128**
INDICATIONS	Zortress is approved for the prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a kidney transplant. Zortress is approved for the prophylaxis of allograft rejection in adult patients receiving a liver transplant, administered no earlier than 30 days post-transplant concurrently in combination with reduced doses of tacrolimus and with corticosteroids.
CRITERIA	ConnectiCare will consider Zortress to be medically necessary in patients who met the following criteria: • Patient must have a documented kidney transplant; **AND** • Zortress is being administered in combination with basiliximab (Simulect) induction and concurrently with reduced doses of cyclosporine and corticosteroids; **AND** • Patient is at low to moderate immunogenic risk; **AND** • Patient is ≥18 years of age OR • Patient must have a documented liver transplant; **AND** • Zortress is being administered no early than 30 days post-transplant with low dose tacrolimus and corticosteroids; **AND** • Patient is ≥18 years of age Therapeutic drug monitoring (TDM) of everolimus and tacrolimus is recommended for all patients receiving these products.
REFERENCES	1. Zortress® [package insert]. East Hanover, NJ: Novartis; 2018.
P&T REVIEW HISTORY	12/11, 10/12, 10/13, 10/14, 11/15, 2/16, 5/17, 5/18, 5/19
REVISION RECORD	2/13, 5/19